/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Candel Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$5.03 0.1357(13.57%) CADL at 04 Dec 2025 04:27 PM Biotechnology
Lowest Today 4.46
Highest Today 5.035
Today’s Open 4.46
Prev. Close 4.42
52 Week High 14.60
52 Week Low 4.25
Day’s Range: Low 4.46 High 5.035
52-Week Range: Low 4.25 High 14.60
1 day return -
1 Week return +5.45
1 month return -2.04
3 month return +2.54
6 month return -10.33
1 year return +13.8
3 year return +161.97
5 year return -
10 year return -

Institutional Holdings

FMR Inc 15.00

Fidelity Select Biotechnology 10.10

BlackRock Inc 4.19

Vanguard Group Inc 3.26

Portolan Capital Management, LLC 2.95

Fidelity Growth Compy Commingled Pl S 2.25

Vanguard Total Stock Mkt Idx Inv 1.97

iShares Russell 2000 ETF 1.71

Fidelity Growth Company Fund 1.65

Geode Capital Management, LLC 1.65

Strategic Advisers U.S. Total Stock 1.60

Halter Ferguson Financial Inc 1.41

State Street Corp 1.19

BANOR SICAV Rosemary S EUR Acc 0.80

Sands Capital Ventures, LLC 0.74

Fidelity Small Cap Index 0.72

Vanguard Institutional Extnd Mkt Idx Tr 0.71

Two Sigma Investments LLC 0.67

Baker Bros Advisors LP 0.65

Susquehanna International Group, LLP 0.64

iShares Russell 2000 Growth ETF 0.57

Northern Trust Corp 0.52

Fidelity Growth Company K6 0.51

Fidelity Series Growth Company 0.48

Fidelity Extended Market Index 0.36

Tanager Wealth Management LLP 0.36

Vanguard Russell 2000 ETF 0.34

Renaissance Technologies Corp 0.30

Marshall Wace Asset Management Ltd 0.29

Aesculape SRI IC 0.26

CREF Stock R3 0.21

State St Russell Sm Cap® Indx SL Cl I 0.21

Charles Schwab Investment Management Inc 0.21

Morgan Stanley - Brokerage Accounts 0.21

Schwab Small Cap Index 0.18

NT R2000 Index Fund - NL 0.17

Nuveen, LLC 0.17

iShares Micro-Cap ETF 0.16

Bank of New York Mellon Corp 0.16

Wellington Management Company LLP 0.16

Market Status

Strong Buy: 3

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 242.65 M

PB Ratio 3.2682

PE Ratio 0.0

Enterprise Value 182.11 M

Total Assets 106.87 M

Volume 1210882

Company Financials

Annual Revenue FY23:31000 0.0M, FY22:125000 0.1M, FY21:125000 0.1M, FY20:125000 0.1M, FY19:125000 0.1M

Annual Profit FY23:null 0.0M, FY22:125000 0.1M, FY21:125000 0.1M, FY20:125000 0.1M, FY19:125000 0.1M

Annual Net worth FY23:-31927000 -31.9M, FY22:-2866000 -2.9M, FY21:-36124000 -36.1M, FY20:-22174000 -22.2M, FY19:-8014000 -8.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-195000 -0.2M, Q2/2025:-242000 -0.2M, Q1/2025:-245000 -0.2M, Q3/2024:null 0.0M, Q2/2024:-249000 -0.2M

Quarterly Net worth Q3/2025:-11269000 -11.3M, Q2/2025:-4796000 -4.8M, Q1/2025:7379000 7.4M, Q3/2024:-10646000 -10.6M, Q2/2024:-22237000 -22.2M

Fund house & investment objective

Company Information Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Organisation Biotechnology

Employees 38

Industry Biotechnology

CEO Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow